{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:08:25Z","timestamp":1767704905755},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,7,11]],"date-time":"2006-07-11T00:00:00Z","timestamp":1152576000000},"content-version":"vor","delay-in-days":7830,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[1985,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ticlopidine, a platelet antiaggregant, has shown some efficacity in a clinical trial in patients with sickle cell disease. We have studied this agent in vitro to evaluate its effects on sickle erythrocyte. Ticlopidine effects sickling in vitro not by direct interaction with hemoglobin, but via strong binding to the red cell membrane. The density of the whole cell population is decreased when cells are treated with 0.1 mM ticlopidine, which is higher than the concentrations of 1 \u03bcM potentially achievable in vivo. Since hemoglobin concentration influences the delay time for gelling, its decrease in the red cell could have a beneficial effect. Such a partial inhibition of the polymerization is shown by oxygen equilibrium studies at various ionic strengths.<\/jats:p>","DOI":"10.1002\/ajh.2830180203","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T10:04:05Z","timestamp":1172052245000},"page":"121-130","source":"Crossref","is-referenced-by-count":4,"title":["Membrane expansion as a mechanism explaining the antisickling action of ticlopidine observed in vitro"],"prefix":"10.1002","volume":"18","author":[{"given":"Magali","family":"Sablayrolles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Wajcman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jena\u2010Paul","family":"Castaigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Labie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,11]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.153.3732.145"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.71.12.4718"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(77)90350-3"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.870976"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.68.6.1180"},{"key":"e_1_2_1_7_2","first-page":"1381","article-title":"Carbamylphosphate mediated inhibition of the sickling of erythrocyte in vitro","volume":"44","author":"Kraus L","year":"1971","journal-title":"Biochem Biophys Res Commun"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1073\/pnas.73.9.3288","article-title":"Inhibition of erythrocyte sickling by cystamine, a thiol reagent","volume":"73","author":"Hassan W","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_2_1_9_2","first-page":"313","article-title":"Extracorporeal treatment of erythrocytes in sickle cell anemia: Hemoglobin carbamylation","volume":"40","author":"Diedrich D","year":"1980","journal-title":"Texas Reports on Biology and Medicine"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood.V47.4.621.621","article-title":"Delay time of gelation: A possible determinant of clinical severity in sickle cell disease","volume":"47","author":"Eaton WA","year":"1976","journal-title":"Blood"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V58.6.1057.1057"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198011133032002"},{"key":"e_1_2_1_13_2","first-page":"58a","article-title":"Trials of DDAVP for production of hyponatremia (low Na) to treat sickle cell anemia (SS) crises in adults","volume":"58","author":"Charache S","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(74)80495-X"},{"key":"e_1_2_1_15_2","unstructured":"CabannesR LonsdorferJ SangareA OndoA PlassartP ZohounI CastaigneJP:Clinical trials in sickle cell crisis with ticlopidine. Sixth Meet Eur Afri Division Int Soc Haematol Athens 1981 p184(Abstract)."},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0076-6879(81)76157-3"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00803a007"},{"key":"e_1_2_1_18_2","volume-title":"The Haemolytic Anemias","author":"Dacie J","year":"1954"},{"key":"e_1_2_1_19_2","first-page":"668","article-title":"Determination of density distribution of red cell population","volume":"64","author":"Danon D","year":"1964","journal-title":"J Lab Clin Med"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(78)90737-6"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1975.tb00548.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(82)90640-2"},{"key":"e_1_2_1_23_2","unstructured":"BrewerGJ BerezaU MizukamiI AsterJC BrewerLF:Drug action hypothesis: How membrane expansion calmodulin inhibition and sickle cell therapy relate. The red cell Fifth Ann Arbor Conf p187 1981."},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(81)90253-4"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.71.11.4457"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110367"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110485"},{"key":"e_1_2_1_28_2","first-page":"345","article-title":"Cell density profile as a measure of erythrocyte hydration: Therapeutic alteration of salt and water content in normal and S\/S red blood cells","volume":"6","author":"Orringer EP","year":"1980","journal-title":"Blood Cells"},{"key":"e_1_2_1_29_2","first-page":"9","article-title":"Heterogeneity of red cells in the sickler: A characteristic with practical clinical and pathophysiological implications","volume":"8","author":"Fabry M","year":"1982","journal-title":"Blood Cells"},{"key":"e_1_2_1_30_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood.V55.2.265.265","article-title":"Cetiedil: Its potential usefulness in sickle cell disease","volume":"55","author":"Benjamin LJ","year":"1980","journal-title":"Blood"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.2830180203","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.2830180203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T05:42:38Z","timestamp":1697866958000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.2830180203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1985,2]]}},"alternative-id":["10.1002\/ajh.2830180203"],"URL":"https:\/\/doi.org\/10.1002\/ajh.2830180203","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,2]]}}}